SAN DIEGO, March 6, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class North America Index (formerly part of the Dow Jones Sustainability Indices), and recognized for the fourth year in a row as a Sustainability Yearbook Member. Illumina, which scored in the top 15% of the Best-in-Class World Index, also ranked as the highest-scoring US company in the Life Sciences Tools & Services Sector.
The Dow Jones Best-in-Class Indices are based on the S&P Global Corporate Sustainability Assessment annual evaluation of companies' sustainability practices. The Best-in-Class Indices represent the top 10% of each industry in the World Index and the top 20% for the North America Index.
"Together with our customers, Illumina is shaping a more sustainable future for all and championing human health to benefit patients, communities, our people, and the planet," said Kevin Pegels, chief of global operations. "I'm incredibly proud of our global team for continuing to achieve this important recognition year after year."
The S&P Global Sustainability Yearbook this year highlights the top 780 companies leading in their industry out of nearly 7700 companies assessed.
Illumina's commitment to increasing the sustainability of its business and products was further demonstrated in 2024 with the launch of the MiSeq i100 Series, which included key innovations, such as an 85% reduction in packaging waste compared to the MiSeq System, and the use of recyclable plastics. The XLEAP-SBS chemistry on the MiSeq i100 Series also enables room-temperature ship-and-store consumables, empowering customers to sequence more sustainably.
Additionally, for the third consecutive year, Illumina procured 100% renewable energy for its operations through on-site generation, purchased renewable electricity, and renewable energy credits, which helped the company earn the fifth spot in TIME's "World's Most Sustainable Companies of 2024'" list.
Updates and progress on Illumina's environmental targets will be disclosed in its 2024 Corporate Social Responsibility (CSR) report, set to release in May. Illumina's most recent CSR report is available here.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Christine Douglass
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$75.76 |
| Daily Change: | -3.82 -4.80 |
| Daily Volume: | 3,648,577 |
| Market Cap: | US$12.020B |
May 01, 2025 April 15, 2025 March 25, 2025 March 19, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
